Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MAXAIR vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle via increased intracellular c AMP.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Prevention and treatment of bronchospasm in patients with reversible obstructive airway disease (e.g., asthma, COPD)
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
2 inhalations (340 mcg) via oral inhalation every 4-6 hours as needed for bronchospasm; not to exceed 12 inhalations per day.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
3.5–4.0 hours; clinically, this supports dosing every 4–6 hours as needed.
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Primarily hepatic via glucuronidation and sulfate conjugation; also metabolized by catechol-O-methyltransferase (COMT).
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Renal excretion of unchanged drug accounts for approximately 90% of elimination; fecal excretion is minimal (<5%).
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
55–70%, primarily to albumin.
92-96%, primarily to albumin and alpha-1-acid glycoprotein
2.0–2.5 L/kg; indicates extensive distribution into tissues.
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Inhalation: approximately 20–30% of the delivered dose reaches the systemic circulation; oral bioavailability is <1% due to first-pass metabolism.
Oral: 40-50%; Inhalation: 20-30%
No specific dose adjustment required; medication is primarily hepatically metabolized.
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
No specific dose adjustment guidelines; use caution in severe hepatic impairment due to potential decreased drug clearance.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Children 6-11 years: 1-2 inhalations (170-340 mcg) via oral inhalation every 4-6 hours as needed; maximum 8 inhalations per day. Children ≥12 years: same as adult.
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
No specific dose adjustment; monitor for increased sensitivity to beta-agonists (e.g., tachycardia, tremor) and concurrent diseases (e.g., cardiovascular disorders).
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
No FDA boxed warning.
No FDA black box warning.
Paradoxical bronchospasm,Cardiovascular effects (tachycardia, arrhythmias, hypertension),Hypokalemia,Hyperglycemia,Immediate hypersensitivity reactions
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Hypersensitivity to pirbuterol or any component,Pre-existing cardiac arrhythmias (e.g., tachyarrhythmias)
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
No specific food interactions. Avoid excessive caffeine intake as it may increase stimulant effects. Grapes, grapefruit, and grapefruit juice have no significant interaction with pirbuterol.
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
FDA Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, maxair (pirbuterol) showed no teratogenic effects at doses up to 20 mg/kg/day in rats and up to 10 mg/kg/day in rabbits, but fetal growth retardation and increased mortality were observed at maternally toxic doses. Risk to human fetus cannot be ruled out. Use during pregnancy only if potential benefit justifies potential risk.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
Unknown if pirbuterol is excreted in human milk. Due to lack of data and potential for serious adverse reactions in nursing infants, caution is advised. M/P ratio not determined.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
No specific pharmacokinetic data in pregnancy; standard dosing recommended. Beta-agonists may delay preterm labor; use with caution.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
MAXAIR (pirbuterol) is a beta-2 adrenergic agonist for asthma and COPD. Use with caution in patients with cardiovascular disorders, especially coronary insufficiency, arrhythmias, or hypertension. Monitor for paradoxical bronchospasm; if occurs, discontinue immediately. Not indicated for acute severe asthma exacerbations unless patient is closely monitored. Can cause hypokalemia, especially with concomitant use of corticosteroids or diuretics. Administer with a spacer device to improve lung deposition and reduce oral side effects.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Use only as prescribed; do not exceed recommended doses.,Rinse mouth after inhalation to prevent oral thrush.,Contact doctor if symptoms worsen or if you need more than usual doses.,Do not share the inhaler; keep it clean.,Seek immediate medical help if you experience chest pain, rapid heartbeat, or severe wheezing after use.,Inform your doctor if you have heart disease, high blood pressure, seizures, or diabetes.,Avoid using with other asthma medications without consulting your doctor.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MAXAIR vs AEROLATE III, answered by our medical review team.
MAXAIR is a Bronchodilator that works by Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle via increased intracellular c AMP.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MAXAIR and AEROLATE III depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MAXAIR is: 2 inhalations (340 mcg) via oral inhalation every 4-6 hours as needed for bronchospasm; not to exceed 12 inhalations per day.. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MAXAIR and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MAXAIR is classified as Category C. FDA Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, maxair (pirbuterol) showed no teratogenic effects at doses up to 20 mg/kg/da. AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.